EN
Turkish Ambassador to China Visits SINOVAC in Beijing
Ambassador Musa and SINOVAC Chairman Explore Continued Investment and Cooperation
On November 8, Dr. Ismail Hak Musa, Turkish Ambassador to China, visited Sinovac Biotech Ltd. ("SINOVAC" or the "Company") in Beijing to meet with Mr. Weidong Yin, Chairman, President, and CEO of SINOVAC. The two parties explored opportunities for SINOVAC's further investment and collaboration in Türkiye following the recent inauguration of KeyVac, a SINOVAC joint venture in Ankara that significantly boosts local vaccine production capacity.
Ambassador Musa advocated for continued SINOVAC investments, while Mr. Yin underscored how the Company's commitment to expanding its presence and operations, as well as expressed his expectation on gaining more support from the Turkish government.
During his visit, Ambassador Musa toured SINOVAC's state-of-the-art COVID-19 vaccine production area with Ms. Helen Yang, Chief Business Officer of SINOVAC, for additional insights into the Company's vaccine development and production.
The meeting focused on SINOVAC's deepening engagement with the Turkish government, following President Recep Tayyip Erdoğan's attendance at the inauguration ceremony of KeyVac's vaccine production center, on October 31. There, the president emphasized the strategic importance of local vaccine production after the COVID-19 pandemic. With KeyVac's added capabilities, Türkiye can produce the hepatitis A vaccine to high standards domestically he said, adding that the plant benefits not only the city of Ankara, but all of Türkiye and its people.
KeyVac, firstly broke ground in November 2021, a vaccine company with the production capacity of 30 million doses per year. Leveraging SINOVAC's cutting-edge technology, KeyVac will develop, produce, and supply vaccines that meet Türkiye's local immunization plan, beginning with the hepatitis A vaccine. KeyVac obtained Good Manufacturing Practice (GMP) certification for producing hepatitis A vaccines in October 2023.
SINOVAC has long served as a key ally in Türkiye's national healthcare efforts, supplying the country with millions of doses of its vaccines and supporting local communities in the fight against infectious diseases, such as varicella and COVID-19. During the pandemic, SINOVAC's joint research with Turkish scientists on the COVID-19 inactivated vaccine was published in the world-leading academic journal The Lancet and played an important role providing crucial scientific evidence for the vaccine’s global deployment. This scientific partnership has fostered innovation and earned trust for SINOVAC’s mission to supply vaccines to eliminate human diseases.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a global biopharmaceutical company headquartered in China. Guided by its mission to “Supply Vaccines to Eliminate Human Diseases,” the Company is dedicated to the research, development, manufacturing and supply of vaccines and related biological products, providing vaccine products and related solutions for disease prevention and control worldwide.
SINOVAC has a diversified vaccine portfolio across multiple disease areas, including influenza, viral hepatitis, varicella, hand, foot and mouth disease (HFMD), poliomyelitis, rabies, tetanus, and pneumococcal disease. Three of SINOVAC's vaccines have been prequalified by the World Health Organization: the inactivated hepatitis A vaccine Healive®, the Sabin-strain inactivated poliomyelitis vaccine (sIPV), and the live attenuated varicella vaccine.
SINOVAC has extensive experience in vaccine research, development and commercialization for emerging infectious diseases and public health emergencies. The Company initiated vaccine R&D in response to major public health threats, including SARS, H5N1, H1N1, and COVID-19, and developed the world's first inactivated SARS vaccine (with Phase I clinical trials completed), China's first inactivated pandemic influenza vaccine against H5N1 (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the world's most widely used inactivated COVID-19 vaccine. Beyond its marketed portfolio, SINOVAC continues to advance its R&D pipeline, spanning combination vaccines, recombinant protein vaccines, mRNA technologies, antibody-based products, and other next-generation technologies and product platforms, while expanding its capabilities in disease prevention and biopharmaceuticals.
With a long-standing commitment to innovation and global health, SINOVAC continues to deepen collaboration with research institutions, international organizations, and local partners while expanding its global presence. Through technological collaboration, localized production, and industrial partnerships, the Company aims to improve access to high-quality vaccines across regions, better address local disease prevention and healthcare needs, and strengthen preparedness for future public health challenges.
For more information, please see the Company's website at www.sinovac.com.